The aim of the present work has been the mass spectrometry characterization of the Nimotuzumab (NIM) antibody chemically modified with the bifunctional chelating agent para-S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraaza cyclododecanetetraacetic acid (p-SCN-Bn-DOTA). The conjugate, upon labeling with the pure β−-emitter 90Y3+ , could represent a promising candidate as radiotracer for an innovative radio-guided surgery (RGS) technique, developed and patented by researchers of our group, which uses a probe system for intraoperative detection of tumor residues exploiting the selective uptake of β−-emitting tracers. The results reported in this study show that multiple DOTA molecules bind to lysine residues of both light and heavy chains of the antibody and, probably, some of them are linked to the variable region of antibody. Moreover, the new mass spectrometric analysis highlights the presence of unreacted NIM in the final product. The information obtained by this work is of fundamental importance in the perspective to utilize this conjugate as a radiocompound after its labeling with 90Y3+ radioisotope. Indeed, the conjugation efficiency and the presence of unreacted NIM affect the specific activity of the final radiotracer which binds specific receptor. © 2018

Mass spectrometry characterization of DOTA-Nimotuzumab conjugate as precursor of an innovative β − tracer suitable in radio-guided surgery / Martelli, C.; Marzano, V.; Marini, F.; Scotognella, T.; Fratoddi, I.; Venditti, I; Rotili, D.; Solfaroli C., E.; Collamati, F.; Mancini T., C.; Morganti, S.; Maccora, D.; Faccini, R.; Cartoni, A; Giordano, A.; Castagnola, M.. - In: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. - ISSN 0731-7085. - STAMPA. - 156:(2018), pp. 8-15. [10.1016/j.jpba.2018.03.018]

Mass spectrometry characterization of DOTA-Nimotuzumab conjugate as precursor of an innovative β − tracer suitable in radio-guided surgery

Fratoddi, I.;Rotili, D.;Collamati, F.;Mancini T. , C.;Faccini, R.;Cartoni, A
;
2018

Abstract

The aim of the present work has been the mass spectrometry characterization of the Nimotuzumab (NIM) antibody chemically modified with the bifunctional chelating agent para-S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraaza cyclododecanetetraacetic acid (p-SCN-Bn-DOTA). The conjugate, upon labeling with the pure β−-emitter 90Y3+ , could represent a promising candidate as radiotracer for an innovative radio-guided surgery (RGS) technique, developed and patented by researchers of our group, which uses a probe system for intraoperative detection of tumor residues exploiting the selective uptake of β−-emitting tracers. The results reported in this study show that multiple DOTA molecules bind to lysine residues of both light and heavy chains of the antibody and, probably, some of them are linked to the variable region of antibody. Moreover, the new mass spectrometric analysis highlights the presence of unreacted NIM in the final product. The information obtained by this work is of fundamental importance in the perspective to utilize this conjugate as a radiocompound after its labeling with 90Y3+ radioisotope. Indeed, the conjugation efficiency and the presence of unreacted NIM affect the specific activity of the final radiotracer which binds specific receptor. © 2018
2018
conjugate; mass spectrometry; monoclonal antibodies; radio-guided surgery; tumor resection
01 Pubblicazione su rivista::01a Articolo in rivista
Mass spectrometry characterization of DOTA-Nimotuzumab conjugate as precursor of an innovative β − tracer suitable in radio-guided surgery / Martelli, C.; Marzano, V.; Marini, F.; Scotognella, T.; Fratoddi, I.; Venditti, I; Rotili, D.; Solfaroli C., E.; Collamati, F.; Mancini T., C.; Morganti, S.; Maccora, D.; Faccini, R.; Cartoni, A; Giordano, A.; Castagnola, M.. - In: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS. - ISSN 0731-7085. - STAMPA. - 156:(2018), pp. 8-15. [10.1016/j.jpba.2018.03.018]
File allegati a questo prodotto
File Dimensione Formato  
Martelli_Mass-spectrometry_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.78 MB
Formato Adobe PDF
1.78 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1118719
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 4
social impact